Innovation got us into the obesity epidemic. And it can get us out — so long as policy-makers don’t get in the way.
A new class of weight-loss drugs such as Ozempic or Wegovy, known as GLP-1 agonists, is transforming how Americans treat obesity, with vast potential benefits for both patients and taxpayers. But just as we’re beginning to understand the promise and enormous value of these therapies, lawmakers like Bernie Sanders are warning that the drugs could “bankrupt our entire health care system” and urging that bureaucrats take over and the government impose strict price controls.
Comments